Trademark: 97830256
Word
MAGNITUDE CLINICAL TRIAL
Status Date
Tuesday, March 26, 2024
Filing Date
Thursday, March 9, 2023
Published for Opposition
Tuesday, April 30, 2024
35 Organizing and recruiting patients for clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
44 Medical treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
42 Scientific research in the nature of conducting clinical trials for the treatment of transthyretin (ATTR) amyloidosis using in vivo gene editing technology
The mark consists of the word "MAGNITUDE" in red-orange, with the words "CLINICAL TRIAL" in gray appearing below the wording and a stylized design of the sun appearing above in shading from red-orange at the top to orange to yellow at the bottom.
The color(s) red-orange, orange, yellow and gray is/are claimed as a feature of the mark.
"CLINICAL TRIAL"
Apr 10, 2024
Notification Of Notice Of Publication E-Mailed
Mar 22, 2024
Approved For Pub - Principal Register
Feb 23, 2024
Teas/Email Correspondence Entered
Feb 23, 2024
Correspondence Received In Law Office
Feb 23, 2024
Teas Response To Office Action Received
Dec 23, 2023
Notification Of Examiner's Amendment/Priority Action E-Mailed
Dec 23, 2023
Examiner's Amendment/Priority Action E-Mailed
Dec 23, 2023
Combined Examiner's Amendment/Priority Action Automatic Entry
Dec 23, 2023
Examiners Amendment And/Or Priority Action - Completed
Dec 7, 2023
Assigned To Examiner
Mar 30, 2023
Notice Of Design Search Code E-Mailed
Mar 29, 2023
New Application Office Supplied Data Entered
Mar 13, 2023
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
